5KOS
Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor
5KOS の概要
| エントリーDOI | 10.2210/pdb5kos/pdb |
| 関連するPDBエントリー | 5KOQ 5KOT |
| 分子名称 | Renin, 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-~{tert}-butyl-4-(3-methoxypropylamino)-~{N}-(2-methylpropyl)-~{N}-[(3~{S},5~{R})-5-morpholin-4-ylcarbonylpiperidin-3-yl]pyrimidine-5-carboxamide, ... (6 entities in total) |
| 機能のキーワード | protein-inhibitor complex, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor |
| 由来する生物種 | Homo sapiens (Human) |
| 細胞内の位置 | Secreted: P00797 |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 76458.68 |
| 構造登録者 | Snell, G.P.,Behnke, C.A.,Okada, K.,Hideyuki, O.,Sang, B.-C.,Lane, W. (登録日: 2016-07-01, 公開日: 2016-11-16, 最終更新日: 2024-11-13) |
| 主引用文献 | Imaeda, Y.,Tokuhara, H.,Fukase, Y.,Kanagawa, R.,Kajimoto, Y.,Kusumoto, K.,Kondo, M.,Snell, G.,Behnke, C.A.,Kuroita, T. Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor. Acs Med.Chem.Lett., 7:933-938, 2016 Cited by PubMed Abstract: The aspartic proteinase renin is an attractive target for the treatment of hypertension and cardiovascular/renal disease such as chronic kidney disease and heart failure. We introduced an S1' site binder into the lead compound guided by structure-based drug design (SBDD), and further optimization of physicochemical properties led to the discovery of benzimidazole derivative (1-(4-methoxybutyl)--(2-methylpropyl)--[(3,5)-5-(morpholin-4-yl)carbonylpiperidin-3-yl]-1benzimidazole-2-carboxamide hydrochloride, TAK-272) as a highly potent and orally active renin inhibitor. Compound demonstrated good oral bioavailability (BA) and long-lasting efficacy in rats. Compound is currently in clinical trials. PubMed: 27774132DOI: 10.1021/acsmedchemlett.6b00251 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.41 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






